---
title: "Top 10 港股跌幅（10月27日）"
description: "億都 (國際控股)(00259) 跌 22.38%，成交额 6074.8 万港元，年内累计涨 275.8%。 山高控股 (00412) 跌 18.64%，成交额 2.6 亿港元，年内累计跌 70.4%。 冠轈控股 (01872) 跌 13.91%，成交额 1550.1 万港元，年内累计涨 485.6%。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/262843029.md"
published_at: "2025-10-27T08:31:11.000Z"
---

# Top 10 港股跌幅（10月27日）

> 億都 (國際控股)(00259) 跌 22.38%，成交额 6074.8 万港元，年内累计涨 275.8%。 山高控股 (00412) 跌 18.64%，成交额 2.6 亿港元，年内累计跌 70.4%。 冠轈控股 (01872) 跌 13.91%，成交额 1550.1 万港元，年内累计涨 485.6%。

恆生指數涨 1.05%，年内累計涨 31.8%；恆生科技指數涨 1.83%，年内累計涨 38.1%。

億都 (國際控股)(00259) 跌 22.38%，成交额 6074.8 万港元，年内累计涨 275.8%。

山高控股 (00412) 跌 18.64%，成交额 2.6 亿港元，年内累计跌 70.4%。

冠轈控股 (01872) 跌 13.91%，成交额 1550.1 万港元，年内累计涨 485.6%。

### Related Stocks

- [00259.HK - 億都(國際控股)](https://longbridge.com/zh-HK/quote/00259.HK.md)
- [00412.HK - 山高控股](https://longbridge.com/zh-HK/quote/00412.HK.md)
- [01872.HK - 冠轈控股](https://longbridge.com/zh-HK/quote/01872.HK.md)
- [02367.HK - 鉅子生物](https://longbridge.com/zh-HK/quote/02367.HK.md)
- [00931.HK - 中國港能](https://longbridge.com/zh-HK/quote/00931.HK.md)
- [02591.HK - 銀諾醫藥-B](https://longbridge.com/zh-HK/quote/02591.HK.md)
- [09878.HK - 匯通達網絡](https://longbridge.com/zh-HK/quote/09878.HK.md)
- [02411.HK - 百果園集團](https://longbridge.com/zh-HK/quote/02411.HK.md)
- [02670.HK - 雲跡](https://longbridge.com/zh-HK/quote/02670.HK.md)
- [09688.HK - 再鼎醫藥](https://longbridge.com/zh-HK/quote/09688.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Zai Lab Sets February 26 Board Meeting to Approve and Release 2025 Annual Results | Zai Lab Ltd has scheduled a board meeting for February 26, 2026, to approve its audited financial results for the year e | [Link](https://longbridge.com/zh-HK/news/275665019.md) |
| Huitongda Network Acquires 25% Stake in Target Company | Huitongda Network Co. Ltd. has acquired a 25% stake in a target company after the approval of a Restructuring Investment | [Link](https://longbridge.com/zh-HK/news/274634881.md) |
| Shenzhen Pagoda Seeks Share-Issue Mandate Refresh After Heavy Utilisation | Shenzhen Pagoda Industrial (Group) Corp. Ltd. plans to refresh its share-issue mandate to allow the issuance of new shar | [Link](https://longbridge.com/zh-HK/news/274577368.md) |
| Guangzhou Innogen Wins Approval to Start Trials on Pet Diabetes Drug Efsubaglutide Alfa | Guangzhou Innogen Pharmaceutical Group has received approval from China's Ministry of Agriculture and Rural Affairs to s | [Link](https://longbridge.com/zh-HK/news/274887236.md) |
| Pagoda Commercial Management meldet für das Jahr 2025 einen unveränderten Umsatz und einen Nettogewinn von 0,65 RMB; die Daten sind ungeprüft | Pagoda Commercial Management, a subsidiary of Shenzhen Pagoda Industrial Group Corp. Ltd., reported preliminary results  | [Link](https://longbridge.com/zh-HK/news/274528859.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。